Secarna Pharmaceuticals And Orbit Discovery Enter Collaboration To Discover And Develop Peptide-Conjugated Targeted Antisense Oligonucleotide Therapeutics
Secarna Pharmaceuticals collaborates with Orbit Discovery to develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

